Entering text into the input field will update the search result below

XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B

Dec. 07, 2019 3:46 PM ETXBiotech Inc. (XBIT) Stock, JNJ StockJNJ, XBITBy: Douglas W. House, SA News Editor23 Comments
  • XBiotech (NASDAQ:XBIT) inks an agreement with Johnson & Johnson (NYSE:JNJ) unit Janssen Biotech for global rights to anti-inflammatory candidate bermekimab.
  • Under the terms of the deal, XBIT will receive $750M upfront and up to $600M in milestones. It will also generate additional revenue over the next two years via a manufacturing supply and clinical services agreement with Janssen.
  • XBIT will use the proceeds to fund the advancement of its next generation True Human anti-IL-1⍺ antibody program, additional pipeline candidates and potential stock buybacks.
  • Bermekimab is a monoclonal antibody that binds to (inhibits) the pro-inflammatory protein interleukin-1alpha (IL-1α).
  • Update: The transaction was completed on December 30.

Recommended For You

Related Stocks

SymbolLast Price% Chg
JNJ
--
XBIT
--